About InVivoSIM anti-human CEACAM6 (Tinurilimab Biosimilar) This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Tinurilimab making it ideal for research use. Tinurilimab is a humanized IgG2 monoclonal antibody that targets CEACAM6 (CD66c), a member of the carcinoembryonic antigen-related cell adhesion molecule family. CEACAM6 is overexpressed in various epithelial cancers, including non-small cell lung cancer (NSCLC), pancreatic, gastric, colorectal, and breast cancers, and is associated with tumor progression and poor prognosis. CEACAM6 functions as an immune checkpoint regulator, suppressing the activity of effector T-cells against tumors. By binding to CEACAM6, Tinurilimab may enhance anti-tumor immune responses by relieving this suppression. Additionally, CEACAM6 contributes to epithelial-mesenchymal transition (EMT), invasion, and metastasis, making it a valuable target for cancer research. This biosimilar antibody is well-suited for studies involving CEACAM6-mediated signaling, tumor immunology, and the development of CEACAM6-targeted therapies. InVivoSIM anti-human CEACAM6 (Tinurilimab Biosimilar) Specifications IsotypeHuman IgG2, κ Recommended Isotype Control(s)RecombiMAb human IgG2 isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman CEACAM6 Reported ApplicationsFunctional assays ELISA Immunohistochemistry Western blot Flow cytometry FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
